Personalized tamoxifen: A step closer but miles to go

Clinical Cancer Research

Volumn 16, Issue 17, 2010, Pages 4308-4310

  Bardia, Aditya ^a   Stearns, Vered ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ENDOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ALLELE; CYP2D6 GENE; DRUG TRANSFORMATION; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MODELS, BIOLOGICAL; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; TAMOXIFEN; TREATMENT OUTCOME;

EID: 77956246159     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1506     Document Type: Note

References (12)

1. Schroth W, Hamann U, Fasching PA, et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 2010;16:4468-77.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
3. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64.
4. Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009; 10:825-33.
5. Bardia A, Stearns V. Pharmacogenomics of tamoxifen: ready for prime time? Current Breast Cancer Reports 2010;2:32-41.
6. Bray MS, Boerwinkle E, Doris PA. High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise. Hum Mutat 2001;17:296-304.
7. Jaremko M, Justenhoven C, Abraham BK, et al. MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Hum Mutat 2005;25: 232-8.
8. Rae JM, Cordero KE, Scheys JO, et al. Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics 2003; 13:501-7.
9. Jin Y, Hayes DF, Li L, et al. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 2008;26:5849-54.
10. Borges S, Desta Z, Jin Y, et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010; 50:450-8.
11. Mohla S, Stearns V, Sathyamoorthy N, Rosenfeld MG, Nelson P. The biology of hormone refractory breast and prostate cancer: An NCI workshop report. Cancer Biol Ther 2009;8:1975-85.
12. Goetz MP, Suman VJ, Couch FJ, et al. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 2008;14:5864-8.